MYR Pharmaceuticals — Treatment of HBV & HDV Infections

Career opportunities — Join our team! Privacy Policy




Dmitry Popov, MD, Chief Executive Officer

Dr. Dmitry Popov’s career includes over 30 years of experience in medicine, biotechnology industry and venture capital. Dmitry is Founder and Managing Partner of Maxwell Biotech, a $100M venture capital fund that is solely dedicated to investments in the life sciences sector.  He founded Maxwell Biotech in 2008 and has successfully managed more than 10 venture investments in biotech, pharma and medical device startups in the USA, Germany, UK, South Korea and Russia. Dmitry serves on the boards of numerous international biotech companies. He received his MD from the Moscow Medical University in 1988 and an MBA from the State University — Higher School of Economics in 2001.

Alexander Alexandrov, MD, Founder & Chief Medical Officer

Dr. Alexander Alexandrov has over 20 years of experience in biotech and pharmaceutical business. Prior MYR Pharma, Alexander held executive positions in the German companies Vision7and Fresenius Biotech, where he was responsible for the development of key clinical products. He started his career as a researcher at University Clinic Essen in Germany. Alexander co-founded MYR Pharma in 2011 and has been the key driver of Myrcludex B development from preclinical studies through the advanced clinical stage.  He holds the degrees of Doctor of Medicine from the University of Essen, Germany and Medical Doctor from Nizhny Novgorod Medical Academy, Russia.

Thomas Christély, Chief Financial Officer

Thomas Christély has 30 years of experience in general management, finance as well as corporate & business development, thereof 23 years with private and public biotech & pharma companies in Europe and the US and more than 25 years of management experience at board level. His track record includes substantial collaborations with AstraZeneca, Pfizer, Dainippon Sumitomo, Sankyo and other pharma and biotech companies, multiple financing transactions - including a reverse IPO to the AIM of the London Stock Exchange - as well as M&A, divestments and strategic restructurings. After his studies in Hamburg and Geneva, he received degrees in business administration (equivalent to a master’s degree) and law from the University of Hamburg and was admitted as attorney-at-law.


Norbert Dinauer, PhD, Chief Operations Officer

Dr. Norbert Dinauer has a track record of 20 years in the (bio)-pharmaceutical industry and held leading positions in the field of drug development, applied pharma consulting and business development. He was responsible for setting up pharmaceutical operations for start-up, mid-size and multi-national enterprises overseeing global supply chains and the coordination of  multiple product launches worldwide. Norbert worked both in the originator’s, generics and advanced therapy business and was in charge of FDA/EU registrations and certifications. Norbert graduated as pharmacist at the University of Regensburg, Germany and holds a PhD in pharmaceutical technology/virology and also worked for many years as Qualified Person.

Florian Vogel, Chief Commercial Officer

Florian Vogel brings a broad range of pharmaceutical marketing and business development experience to his role as MYR’s Head of Marketing & Sales. Florian has extensive domestic and international experience in product launches as well as in product life cycle management. Florian held numerous positions in the biopharma industry. He successfully developed the commercial structure in Asia/Pacific as a Regional Director, followed by the establishment of a therapeutic unit within central Europe.  Florian graduated (M.Sc.) from the Grenoble Graduate School of Business in France and received his B.S. in Business Administration from the University of Marburg in Germany.